264 related articles for article (PubMed ID: 33613571)
1. Apremilast in Refractory Behçet's Syndrome: A Multicenter Observational Study.
Vieira M; Buffier S; Vautier M; Le Joncour A; Jamilloux Y; Gerfaud-Valentin M; Bouillet L; Lazaro E; Barete S; Misery L; Gobert D; Goulenok T; Fain O; Sacre K; Sève P; Cacoub P; Comarmond C; Saadoun D
Front Immunol; 2020; 11():626792. PubMed ID: 33613571
[TBL] [Abstract][Full Text] [Related]
2. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome.
Hatemi G; Mahr A; Ishigatsubo Y; Song YW; Takeno M; Kim D; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
N Engl J Med; 2019 Nov; 381(20):1918-1928. PubMed ID: 31722152
[TBL] [Abstract][Full Text] [Related]
3. Apremilast for Behçet's syndrome--a phase 2, placebo-controlled study.
Hatemi G; Melikoglu M; Tunc R; Korkmaz C; Turgut Ozturk B; Mat C; Merkel PA; Calamia KT; Liu Z; Pineda L; Stevens RM; Yazici H; Yazici Y
N Engl J Med; 2015 Apr; 372(16):1510-8. PubMed ID: 25875256
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apremilast for Behçet's syndrome: a real-life single-centre Italian experience.
De Luca G; Cariddi A; Campochiaro C; Vanni D; Boffini N; Tomelleri A; Cavalli G; Dagna L
Rheumatology (Oxford); 2020 Jan; 59(1):171-175. PubMed ID: 31280296
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of apremilast for 3 months in Behçet's disease: A prospective observational study.
Hirahara L; Kirino Y; Soejima Y; Takeno M; Takase-Minegishi K; Yoshimi R; Takeuchi M; Mizuki N; Nakajima H
Mod Rheumatol; 2021 Jul; 31(4):856-861. PubMed ID: 32996801
[TBL] [Abstract][Full Text] [Related]
6. Positioning of apremilast in treatment of Behçet's disease.
Takeno M
Mod Rheumatol; 2020 Mar; 30(2):219-224. PubMed ID: 31747804
[TBL] [Abstract][Full Text] [Related]
7. Use of Apremilast for Aphthous Ulcers in a Patient With Behçet’s Syndrome.
Saini A; Ferguson C; Salkey K
J Drugs Dermatol; 2018 Dec; 17(12):1328-1329. PubMed ID: 30586267
[TBL] [Abstract][Full Text] [Related]
8. Apremilast for oral ulcers associated with active Behçet's syndrome over 68 weeks: long-term results from a phase 3 randomised clinical trial.
Hatemi G; Mahr A; Takeno M; Kim DY; Saadoun D; Direskeneli H; Melikoğlu M; Cheng S; McCue S; Paris M; Chen M; Yazici Y
Clin Exp Rheumatol; 2021; 39 Suppl 132(5):80-87. PubMed ID: 34622764
[TBL] [Abstract][Full Text] [Related]
9. An evaluation of apremilast for the treatment of adult patients with oral ulcers associated with Behçet's syndrome.
Özdede A; Hatemi G
Expert Opin Pharmacother; 2021 Aug; 22(12):1533-1537. PubMed ID: 34218739
[TBL] [Abstract][Full Text] [Related]
10. Apremilast in refractory orogenital ulcers and other manifestations of Behçet's disease. A national multicentre study of 51 cases in clinical practice.
Atienza-Mateo B; Martín-Varillas JL; Graña J; Espinosa G; Moriano C; Pérez-Sandoval T; García-Armario MD; Castellví I; Román-Ivorra JA; Olivé A; Ybáñez A; Martinez-Ferrer A; Narváez J; Romero-Yuste S; Ojeda S; Ros I; Loricera J; Calvo-Río V; Castañeda S; Gonzalez-Gay MA; Blanco R;
Clin Exp Rheumatol; 2020; 38 Suppl 127(5):69-75. PubMed ID: 33331268
[TBL] [Abstract][Full Text] [Related]
11. Real-world effectiveness of apremilast in multirefractory mucosal involvement of Behçet's disease.
Lopalco G; Venerito V; Leccese P; Emmi G; Cantarini L; Lascaro N; Di Scala G; Fabiani C; Rigante D; Iannone F
Ann Rheum Dis; 2019 Dec; 78(12):1736-1737. PubMed ID: 31401548
[No Abstract] [Full Text] [Related]
12. Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet's phenotype: a multicentre study.
Fagni F; Bettiol A; Talarico R; Lopalco G; Silvestri E; Urban ML; Russo PAJ; Di Scala G; Emmi G; Prisco D
Ann Rheum Dis; 2020 Aug; 79(8):1098-1104. PubMed ID: 32381569
[TBL] [Abstract][Full Text] [Related]
13. Apremilast: A Review in Oral Ulcers of Behçet's Disease.
Deeks ED
Drugs; 2020 Feb; 80(2):181-188. PubMed ID: 31933168
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of apremilast on genital ulcers, skin lesions, and arthritis in patients with Behçet's disease: A systematic review and meta-analysis.
Iizuka Y; Takase-Minegishi K; Hirahara L; Kirino Y; Soejima Y; Namkoong HO; Horita N; Yoshimi R; Takeuchi M; Takeno M; Mizuki N; Nakajima H
Mod Rheumatol; 2022 Oct; 32(6):1153-1162. PubMed ID: 34752620
[TBL] [Abstract][Full Text] [Related]
15. Management of skin, mucosa and joint involvement of Behçet's syndrome: A systematic review for update of the EULAR recommendations for the management of Behçet's syndrome.
Leccese P; Ozguler Y; Christensen R; Esatoglu SN; Bang D; Bodaghi B; Celik AF; Fortune F; Gaudric J; Gül A; Kötter I; Mahr A; Moots RJ; Richter J; Saadoun D; Salvarani C; Scuderi F; Sfikakis PP; Siva A; Stanford M; Tugal-Tutkun I; West R; Yurdakul S; Olivieri I; Yazici H; Hatemi G
Semin Arthritis Rheum; 2019 Feb; 48(4):752-762. PubMed ID: 29954598
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of the anti-IL 17 secukinumab in refractory Behçet's syndrome: A preliminary study.
Di Scala G; Bettiol A; Cojan RD; Finocchi M; Silvestri E; Emmi G
J Autoimmun; 2019 Feb; 97():108-113. PubMed ID: 30213443
[TBL] [Abstract][Full Text] [Related]
17. Apremilast in a Japanese subgroup with Behçet's syndrome: Results from a Phase 3, randomised, double-blind, placebo-controlled study.
Takeno M; Dobashi H; Tanaka Y; Kono H; Sugii S; Kishimoto M; Cheng S; McCue S; Paris M; Chen M; Ishigatsubo Y
Mod Rheumatol; 2022 Feb; 32(2):413-421. PubMed ID: 34894266
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apremilast and its impact on serum cytokine levels in patients with Behçet's disease.
Wakiya R; Ushio Y; Ueeda K; Kameda T; Shimada H; Nakashima S; Kato M; Miyagi T; Sugihara K; Mizusaki M; Mino R; Kadowaki N; Dobashi H
Dermatol Ther; 2022 Aug; 35(8):e15616. PubMed ID: 35668044
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of apremilast against Behçet's disease-associated mucocutaneous and joint involvement confirmed through switching from adalimumab.
Azuma N; Matsui K
Clin Exp Rheumatol; 2022 Sep; 40(8):1605-1606. PubMed ID: 36106543
[No Abstract] [Full Text] [Related]
20. Long-Term Outcome of Ustekinumab Therapy for Behçet's Disease.
Mirouse A; Barete S; Desbois AC; Comarmond C; Sène D; Domont F; Bodaghi B; Ferfar Y; Cacoub P; Saadoun D;
Arthritis Rheumatol; 2019 Oct; 71(10):1727-1732. PubMed ID: 31008548
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
